Spring Creek Capital’s eFFECTOR Therapeutics, Inc. Warrant EFTRW Stock Holding History

Spring Creek Capital’s Portfolio EFTRW Stock Details EFTRW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-66,666	Closed	-$67K	–	599
2021 Q2	$67K	Buy	+66,666	New	+$53.9K	﹤0.01%	469

Other funds holding EFTRW

Aristeia Capital Greenwich, Connecticut $4.82B AUM 24.94% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Highbridge Capital Management New York $3.09B AUM 31.19% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

MMCAP International Grand Cayman, Cayman Islands $1.16B AUM 77.9% 1-Year Est. Return

Monashee Investment Management Boston, Massachusetts $184M AUM 197.43% 1-Year Est. Return

Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return

CVI Holdings Wilmington, Delaware $116M AUM 5.68% 1-Year Est. Return

Wolverine Asset Management Chicago, Illinois $10.4B AUM 4.78% 1-Year Est. Return

Alpine Global Management New York $668M AUM 20.22% 1-Year Est. Return

Spring Creek Capital's EFTRW Position: Q3 2021 in Review

Spring Creek Capital sold out of eFFECTOR Therapeutics, Inc. Warrant (EFTRW) in Q3 2021, closing a stake of 66,666 shares — an estimated $67K sold.

Spring Creek Capital first reported a position in EFTRW in Q2 2021 and held it in 1 quarter. The position peaked at $67K in Q2 2021. 21 funds tracked by Wall St. Rank hold EFTRW as of Q3 2021.

Spring Creek Capital reported no remaining eFFECTOR Therapeutics, Inc. Warrant position as of Q3 2021 after selling out during the quarter.
Spring Creek Capital sold 66,666 eFFECTOR Therapeutics, Inc. Warrant shares in Q3 2021, an estimated $67K.
Spring Creek Capital first reported a position in eFFECTOR Therapeutics, Inc. Warrant in Q2 2021 and held it in 1 quarter.
Spring Creek Capital's eFFECTOR Therapeutics, Inc. Warrant position peaked at $67K in Q2 2021.
21 funds tracked by Wall St. Rank held eFFECTOR Therapeutics, Inc. Warrant as of Q3 2021.

Based on Spring Creek Capital's 13F filing for Q3 2021, filed 15 Nov 2021.